secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001104659-25-097992
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion prices $75M public offering of 30M shares at $2.50 each
----------------------------------------------------------------

- Offering of 30,000,000 shares at $2.50/share; net proceeds ~$70.2M (or ~$80.7M if underwriters' option exercised).
- Expected close October 9, 2025; use proceeds for NEXLETOL/NEXLIZET commercialization, R&D, working capital.
- Piper Sandler & Cantor Fitzgerald are joint book-running managers; co-managers include Citizens JMP, H.C. Wainwright, Needham.
- Shares sold under existing shelf registration statement (File No. 333-286631) effective April 29, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465925097992/0001104659-25-097992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465925097992/tm2527818d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer